Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.250
-0.050 (-3.85%)
At close: Mar 28, 2025, 4:00 PM
1.262
+0.012 (0.94%)
After-hours: Mar 28, 2025, 5:01 PM EDT

Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of $103.72 million. The enterprise value is -$131.99 million.

Market Cap 103.72M
Enterprise Value -131.99M

Important Dates

The last earnings date was Wednesday, March 5, 2025, after market close.

Earnings Date Mar 5, 2025
Ex-Dividend Date n/a

Share Statistics

Editas Medicine has 82.98 million shares outstanding. The number of shares has increased by 8.39% in one year.

Current Share Class 82.98M
Shares Outstanding 82.98M
Shares Change (YoY) +8.39%
Shares Change (QoQ) +0.16%
Owned by Insiders (%) 0.43%
Owned by Institutions (%) 62.75%
Float 82.62M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.31
Forward PS 18.43
PB Ratio 0.80
P/TBV Ratio 0.77
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.26.

Current Ratio 3.75
Quick Ratio 3.71
Debt / Equity 0.26
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -98.10% and return on invested capital (ROIC) is -53.82%.

Return on Equity (ROE) -98.10%
Return on Assets (ROA) -35.52%
Return on Invested Capital (ROIC) -53.82%
Return on Capital Employed (ROCE) -90.38%
Revenue Per Employee $131,358
Profits Per Employee -$963,793
Employee Count 246
Asset Turnover 0.08
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -83.27% in the last 52 weeks. The beta is 1.87, so Editas Medicine's price volatility has been higher than the market average.

Beta (5Y) 1.87
52-Week Price Change -83.27%
50-Day Moving Average 1.51
200-Day Moving Average 2.98
Relative Strength Index (RSI) 41.56
Average Volume (20 Days) 2,455,442

Short Selling Information

The latest short interest is 17.44 million, so 21.02% of the outstanding shares have been sold short.

Short Interest 17.44M
Short Previous Month 17.09M
Short % of Shares Out 21.02%
Short % of Float 21.11%
Short Ratio (days to cover) 1.74

Income Statement

In the last 12 months, Editas Medicine had revenue of $32.31 million and -$237.09 million in losses. Loss per share was -$2.88.

Revenue 32.31M
Gross Profit -166.93M
Operating Income -238.92M
Pretax Income -193.45M
Net Income -237.09M
EBITDA -233.11M
EBIT -238.92M
Loss Per Share -$2.88
Full Income Statement

Balance Sheet

The company has $269.91 million in cash and $35.03 million in debt, giving a net cash position of $234.88 million or $2.83 per share.

Cash & Cash Equivalents 269.91M
Total Debt 35.03M
Net Cash 234.88M
Net Cash Per Share $2.83
Equity (Book Value) 134.27M
Book Value Per Share 1.62
Working Capital 212.09M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$210.28 million and capital expenditures -$8.83 million, giving a free cash flow of -$219.11 million.

Operating Cash Flow -210.28M
Capital Expenditures -8.83M
Free Cash Flow -219.11M
FCF Per Share -$2.64
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -739.37%
Pretax Margin -733.72%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -8.39%
Shareholder Yield -8.39%
Earnings Yield -230.43%
FCF Yield -212.95%

Analyst Forecast

The average price target for Editas Medicine is $8.08, which is 546.40% higher than the current price. The consensus rating is "Buy".

Price Target $8.08
Price Target Difference 546.40%
Analyst Consensus Buy
Analyst Count 14
Revenue Growth Forecast (5Y) -10.02%
EPS Growth Forecast (5Y) -13.97%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Editas Medicine has an Altman Z-Score of -6.26 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -6.26
Piotroski F-Score 1